These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35930482)

  • 1. Progression of large-vessel giant cell arteritis despite tocilizumab treatment.
    Elfishawi M; Kaymakci M; Koster MJ; Warrington KJ
    Clin Exp Rheumatol; 2023 Apr; 41(4):985-986. PubMed ID: 35930482
    [No Abstract]   [Full Text] [Related]  

  • 2. Lights and shadows on the efficacy of tocilizumab monotherapy in large vessel giant cell arteritis.
    González-Gay MÁ; Castañeda S; Heras-Recuero E; Largo R
    Rheumatology (Oxford); 2024 Jan; 63(1):6-7. PubMed ID: 37458478
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.
    Hellmich B; Águeda AF; Monti S; Luqmani R
    Curr Rheumatol Rep; 2020 Oct; 22(12):84. PubMed ID: 33044642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Large-vessel vasculitis-giant cell and Takayasu arteritis].
    Villiger PM
    Internist (Berl); 2019 Oct; 60(10):1059-1073. PubMed ID: 31471629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Does tocilizumab mean the end of glucocorticoids in giant cell arteritis?].
    Samson M; Bonnotte B
    Rev Med Interne; 2018 Feb; 39(2):75-77. PubMed ID: 29217104
    [No Abstract]   [Full Text] [Related]  

  • 6. Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis.
    Palmowski A; Buttgereit F
    Curr Rheumatol Rep; 2020 Oct; 22(12):85. PubMed ID: 33047263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab: a new therapy for large vessel vasculitis.
    Al-Homood IA
    Clin Exp Med; 2014 Nov; 14(4):355-60. PubMed ID: 23949338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
    Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of large-vessel vasculitis.
    Salvarani C; Hatemi G
    Curr Opin Rheumatol; 2019 Jan; 31(1):25-31. PubMed ID: 30461542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy.
    Yoshifuji H
    Mod Rheumatol; 2019 Mar; 29(2):287-293. PubMed ID: 30427262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases.
    Vinicki JP; García-Vicuña R; Arredondo M; López-Bote JP; García-Vadillo JA; Castañeda S; Álvaro-Gracia JM
    Reumatol Clin; 2017; 13(4):210-213. PubMed ID: 27499427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological treatments in giant cell arteritis & Takayasu arteritis.
    Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
    Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment strategies in large-vessel vasculitis.
    Unizony S; Stone JH; Stone JR
    Curr Opin Rheumatol; 2013 Jan; 25(1):3-9. PubMed ID: 23114585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
    Hellmich B; Agueda A; Monti S; Buttgereit F; de Boysson H; Brouwer E; Cassie R; Cid MC; Dasgupta B; Dejaco C; Hatemi G; Hollinger N; Mahr A; Mollan SP; Mukhtyar C; Ponte C; Salvarani C; Sivakumar R; Tian X; Tomasson G; Turesson C; Schmidt W; Villiger PM; Watts R; Young C; Luqmani RA
    Ann Rheum Dis; 2020 Jan; 79(1):19-30. PubMed ID: 31270110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study.
    Saito S; Okuyama A; Okada Y; Shibata A; Sakai R; Kurasawa T; Kondo T; Takei H; Amano K
    Rheumatology (Oxford); 2020 Jul; 59(7):1617-1621. PubMed ID: 31665468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
    Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
    J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic treatment of large-vessel vasculitides.
    Schäfer VS; Zwerina J
    Curr Opin Rheumatol; 2012 Jan; 24(1):31-7. PubMed ID: 22089099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term use of tocilizumab in giant cell arteritis.
    Coath FL; Mukhtyar C
    Rheumatology (Oxford); 2021 Oct; 60(10):4447-4449. PubMed ID: 33956087
    [No Abstract]   [Full Text] [Related]  

  • 19. Tocilizumab in Giant Cell Arteritis.
    Mariano VJ; Frishman WH
    Cardiol Rev; 2018; 26(6):321-330. PubMed ID: 29570475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab in the treatment of giant cell arteritis.
    Leuchten N; Aringer M
    Immunotherapy; 2018 Mar; 10(6):465-472. PubMed ID: 29504436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.